Celebrating 40 Years of Progress in Bone Marrow Transplantation: A Report from the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation

Pagano, Livio; Lyon, Sue

doi:10.2217/fmb.14.95

Cited by 5 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since then, many circumstances have changed, e.g. the preparative regimen, the care procedure and the nursing actions [24,25]. To conclude, the knowledge about FC support needs from before allo-HSCT and during the acute post-transplantation phase is scarce as we could only find one longitudinal study on this topic [17].…”

Section: Introductionmentioning

confidence: 99%

Family caregivers’ support needs during allo-HSCT—a longitudinal study

Kisch

Bergkvist

Alvariza

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

Purpose The study aimed to explore family caregivers’ support needs prior to allo-HSCT, how these change over time and whether they are associated with demographic factors and caregiver outcome. Methods This longitudinal repeated measure study included 87 family caregivers of allo-HSCT recipients: 63% were partners, 74% women, 65% lived with the recipient, and their mean age was 54 years. They completed the 14-item Carer Support Needs Assessment Tool (CSNAT) and caregiver outcome measures (caregiver burden, anxiety, depression, preparedness for caregiving and general health) prior to allo-HSCT and 3, 6 and 16 weeks later. Results The two top support needs prior to allo-HSCT were ‘knowing what to expect in the future’ (79%) and ‘dealing with your own feelings’ (70%). Several support needs were associated with younger age and not being a partner, while higher needs implied worse caregiver outcomes for at least one of the outcomes prior to transplantation. Most support needs remained the same at the last follow-up. Conclusion The findings that high support needs are often associated with worse caregiver outcomes and most support needs do not diminish over time indicate that more attention should be placed on the situation of family caregivers.

show abstract

Section: Introductionmentioning

confidence: 99%

Family caregivers’ support needs during allo-HSCT—a longitudinal study

Kisch

Bergkvist

Alvariza

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Other risk factors have been proposed such as use of voriconazole prophylaxis, and the increasing use of intense immunosuppression [9]. The diagnosis is suspected by the clinical manifestations in susceptible patients with continuous fever despite antibacterial therapy and is confirmed by the detection of the fungus by histological analysis or culture of a tissue specimen taken from a site of disease [5], [10]. There is no serological test currently available for mucormycosis detection.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of severe aplastic anemia with syngeneic stem cell transplantation in the setting of active disseminated mucormycosis

El‐Cheikh¹,

Atoui²,

Moukalled³

et al. 2019

Medical Mycology Case Reports

View full text Add to dashboard Cite

Severe aplastic anemia (SAA) is a hematological disease resulting in pancytopenia due to bone marrow failure. Treatment consists of immunosppressive therapy, or allo-SCT. Patients with aplastic anemia are predisposed to invasive fungal infections due to mucormycosis. Till now, syngeneic SCT in the context of active mucormycosis infection for patients with severe aplastic anemia is lacking in the literature.Here, we report a case of severe aplastic anemia with disseminated mucormycosis infection undergoing syngeneic transplant.

show abstract

“…According to recommendations of the Fifth European Conference on Infections in Leukaemia (ECIL-5), voriconazole remains the first-line treatment in invasive aspergillosis. It is followed by recommendations for LAmB (liposomal amphotericin B) and then ABLC (amphotericin B lipid complex) [22]. The options for salvage therapy include voriconazole (if not used in the first line), caspofungin, LAmB, ABLC, posaconazole, and combination therapy.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin – case study and brief literature review

Barańska

Kroll-Balcerzak

Gil

et al. 2017

cejoi

View full text Add to dashboard Cite

The number of patients with hematological malignancies who develop invasive fungal disease (IFD) has increased dramatically in recent decades. This increase is attributed to impairment of the host immune system due to intensive cytotoxic chemotherapies, use of corticosteroids and profound immunosuppression after hematopoietic stem cell transplantation (HSCT). Additionally, the increasing prevalence of fungal infections caused by emerging and rare pathogens, IFD of mixed etiology or of atypical localization is observed. There are also much more patients with IFD who do not belong to a well-described risk group, like patient with lymphoproliferative disorders. Within this heterogeneous group of patients, IFD epidemiology is not well defined and antifungal prophylaxis practices vary.The aim of this paper is to present the case of a 58-year-old patient with refractory Hodgkin disease, focusing on infectious complication after subsequent lines of chemotherapy. During deep and prolonged neutropaenia the patient developed symptoms of pneumonia. Despite antifungal prophylaxis with fluconazole, IFD of mixed etiology with the presence of Candida glabrata and Aspergillus fumigatus was diagnosed. The infection showed a poor response to monotherapy with liposomal amphotericin B, but was successfully treated with therapy involving micafungin. Analysis of the presented case demonstrated the necessity of new approaches to the prevention of IFD in patients with lymphoproliferative disorders heavily pretreated with numerous chemotherapy protocols. Prolonged neutropenia and high corticosteroid exposure put these patients in high risk of IFD like patients with acute myeloid leukemia/myelodysplastic syndrome or after allogeneic HSCT.

show abstract

Celebrating 40 Years of Progress in Bone Marrow Transplantation: A Report from the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation

Cited by 5 publications

References 17 publications

Family caregivers’ support needs during allo-HSCT—a longitudinal study

Family caregivers’ support needs during allo-HSCT—a longitudinal study

Successful treatment of severe aplastic anemia with syngeneic stem cell transplantation in the setting of active disseminated mucormycosis

Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin – case study and brief literature review

Contact Info

Product

Resources

About